Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03160768 · ClinicalTrials.gov registry record
Feasibility of Isolating P16 Expression
A clinical trial, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- 85
- Enrollment target
NCT03160768 is a clinical trial that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 85 participants.
The verdict
NCT03160768 has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- 85 participants
- Enrollment target
Study Summary
Expression of the cell cycle regulator p16INK4a increases with age and toxic stressors. In mice, both radiation and chemotherapy are known to increase p16. Due to its influence on age-related regenerative capacity, p16 is an excellent candidate biomarker of physiologic reserve that may identify patients able to withstand the stressor of chemotherapy (low p16) from those unlikely to tolerate chemotherapy (high p16). That is, expression of p16 may predict physiologic, rather than chronologic, age. Such findings could have implications for care of cancer survivors and treatment decision-making in cancer patients. STUDY OBJECTIVE: This is an observational pilot study to determine the feasibility of isolating p16INK4a in CD3+ T lymphocytes in adults treated with chemotherapy for cancer during childhood.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2017-05-25 |
| Est. Completion | 2019-05-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03160768
The ClinicalTrials.gov registry entry for NCT03160768 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03160768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03160768 about?
NCT03160768 is a clinical study titled "Feasibility of Isolating P16 Expression". Expression of the cell cycle regulator p16INK4a increases with age and toxic stressors. In mice, both radiation and chemotherapy are known to increase p16. Due to its influence on age-related regenerative capacity, p16 is an excellent candidate biomarker of physiologic reserve that may identify pati...
What is the current status of trial NCT03160768?
This trial is currently completed. The enrollment target is 85 participants. The study started on 2017-05-25. Estimated completion is 2019-05-02.
Who is sponsoring clinical trial NCT03160768?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.